Genomma Lab Internacional Stock Current Liabilities
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company Current Liabilities Analysis
Genomma Lab's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Genomma Lab Internacional has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Genomma Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in current liabilities category among its peers.
Genomma Fundamentals
Return On Equity | 0.13 | |||
Return On Asset | 0.0921 | |||
Profit Margin | 0.08 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 1.09 B | |||
Shares Outstanding | 1 B | |||
Shares Owned By Insiders | 29.00 % | |||
Shares Owned By Institutions | 29.10 % | |||
Price To Earning | 11.09 X | |||
Price To Book | 1.38 X | |||
Price To Sales | 0.05 X | |||
Revenue | 15.49 B | |||
Gross Profit | 9.56 B | |||
EBITDA | 2.84 B | |||
Net Income | 1.31 B | |||
Cash And Equivalents | 1.3 B | |||
Cash Per Share | 1.30 X | |||
Total Debt | 3.83 B | |||
Debt To Equity | 0.51 % | |||
Current Ratio | 1.67 X | |||
Book Value Per Share | 10.98 X | |||
Cash Flow From Operations | 1.47 B | |||
Earnings Per Share | 0.07 X | |||
Number Of Employees | 2.3 K | |||
Beta | 0.53 | |||
Market Capitalization | 973.77 M | |||
Total Asset | 21.54 B | |||
Annual Yield | 0.05 % | |||
Net Asset | 21.54 B | |||
Last Dividend Paid | 0.38 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Fundamental Analysis View fundamental data based on most recent published financial statements |